18F-FLT PET Imaging in Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
2017-12-31
Target enrollment:
Participant gender:
Summary
In the current study, advanced positron emission tomography/computed tomography (PET/CT) and
positron emission tomography/magnetic resonance (PET/MR) imaging methods will be used to
validate our hypothesis that melanoma patients receiving Dual-Immune Checkpoint Blockade
(DICB) therapy, who ultimately achieve clinical benefit, will have an increase, or "FLARE",
in tumor FLT and/or FDG uptake from baseline, as seen after cycle#1 of treatment, and that
after 2 cycles of treatment responders will have a decline in FLT and FDG uptake, in
comparison to the patients classified as "non-responders". In addition, alterations in tumor
apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging
(DW/MRI) will be evaluated, expecting after cycle#1: transient reductions in ADC due to
lymphocyte proliferation, increased cellularity and restriction of water movement in
responding patients, with these patients tumors having increased ADC at 2 cycles into therapy
associated with tumor necrosis. This study will evaluate rather early PET imaging with FLT
and FDG is a useful imaging biomarker of response to DICB.